Hosted on MSN19d
Purple Biotech Stock Hits Nearly 2-Month High On Cancer Drug Trial Success: Retail Thrilled
Shares of Purple Biotech ($PPBT) surged more than 45% on Monday morning, reaching their highest levels since early October.
Purple Biotech Shares Jump on Positive Phase 2 Cancer Drug Study Results
Purple Biotech shares soared in premarket trading Monday after the company reported positive phase two study results for its pancreatic cancer drug Shares traded 68% higher at $5.63.
Why Purple Biotech (PPBT) Stock Is Getting Hammered
Purple Biotech shares are trading lower by 28% during Tuesday's session. The company announced a $2.8 million offering.
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today ...
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement ...